You are using an older browser version. Please use a supported version for the best MSN experience.

DCGI approves anti-Covid drug 2-DG developed by DRDO for emergency use

The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL), Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid-19.

UP NEXT

UP NEXT

More From The Times of India

More From The Times of India

image beaconimage beaconimage beacon